RxDoctor Payments Data

Pradip Mishra, MD

Cardiovascular Disease · Clarksville, TNNPI 1679660096

Payments from drug & device makers

$7,913in general payments, 2019–2025

Across 369 payments — averaging $21.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Boston Scientific$1K
  • Amgen$899
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$894
  • Boehringer Ingelheim$590
  • Abbott$497
  • plus $3K from 25 others

What the payments were for

  • Travel & lodging$96912%
  • Food & beverage$6,92287%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,913 in reported general payments places this provider in the 70th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$295,013
Medicare patients
1,102
Services billed
4,478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban404$460,786
XareltoRivaroxaban173$180,036
EntrestoSacubitril/Valsartan100$116,660
Repatha SureclickEvolocumab103$83,995
FarxigaDapagliflozin Propanediol62$63,235
JardianceEmpagliflozin60$61,938
BrilintaTicagrelor73$42,754
Diltiazem 24hr Er (Cd)Diltiazem Hcl271$10,602
NexletolBempedoic Acid13$10,032
Amiodarone Hcl218$6,723
Metoprolol Succinate378$5,267
Atorvastatin Calcium485$5,101
Nifedipine ErNifedipine133$4,375
Propafenone Hcl59$3,930
Ranolazine ErRanolazine29$3,878

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$169$460,786404 claims
Johnson & JohnsonXarelto$127$180,036173 claims
NovartisEntresto$360$116,660100 claims
AstraZenecaFarxiga, Brilinta$443$105,989135 claims
Boehringer IngelheimJardiance$590$61,93860 claims
Esperion Therapeutics, Inc.Nexletol$110$10,03213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Clarksville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →